The science of Tumor Treating Fields has the potential to extend beyond glioblastoma. Treatment with TTFields has shown a consistent antimitotic effect in our preclinical and clinical research over the last 16 years.

We believe we have gained a deep understanding of the underlying mechanism of action and the multiple pathways through which TTFields exert their effects within dividing cancer cells. Our research shows that TTFields can have an anti-mitotic effect in over 15 different solid tumor types in culture and in eight in vivo tumor models, including some of the most aggressive forms of cancer. We are committed to advancing the science of TTFields across a broad spectrum of solid tumors and bringing our treatment to cancer patients who can benefit from our therapy.

Novocure clinical pipeline

as of February 2017

Pre-clinical
Phase II
Phase III
FDA Approved
Recurrent Glioblastoma
Newly Diagnosed Glioblastoma
Brain Metastasis
Non-small Cell Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Mesothelioma
Trial ongoing
Trial complete

we also have pre-clinical data for Tumor Treating Fields in these areas:

Pre-clinical

  • breast cancer
  • cervical cancer
  • colorectal carcinoma
  • gastric adenocarcinoma
  • hepatocellular carcinoma
  • malignant melanoma
  • renal adenocarcinoma
  • urinary transitional cell carcinoma
  • small cell lung cancer
View All

publications

Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.

Proceedings of the National Academy of Sciences, Volume 104, No. 24, June 12, 2007.

Read Article

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

European Journal of Cancer, Volume 48, No. 12, 2012.

Read Article

Delayed response and survival from NovoTTF-100A in recurrent GBM.

Medical Oncology, Volume 3, No. 338, January 2013.

Read Article

Response assessment of NovoTTF-100A vs best physician’s choice of chemotherapy in recurrent glioblastoma.

Cancer Medicine, Volume 3, No. 3, 2014.

Read Article

Characterization and management of dermatologic adverse events with the NovoTTF-100A system, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.

Seminars in Oncology, Volume 41, S1 – S14, June, 2014.

Read Article

Post hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician’s choice chemotherapy.

Seminars in Oncology, Volume 41, S25 – S34, October, 2014.

Read Article

Response patterns of recurrent glioblastomas treated With Tumor Treating Fields.

Seminars in Oncology, Volume 41, S14 – S24, October, 2014.

Read Article

Clinical practice experience with NovoTTF-100A™ system for glioblastoma: the Patient Registry Dataset (PRiDe).

Seminars in Oncology, Volume 41, S4 – S13, October, 2014.

Read Article

clinical trials

Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types.

We sponsor clinical trials of Tumor Treating Fields in several cancer types. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov.

METIS

Cancer type: Brain metastases from non-small cell lung cancer (Phase 3 pivotal)

Protocol number: NCT02831959

About brain metastases: Metastatic cancer is cancer that has spread from the place where it first started to another place in the body. In metastasis, cancer cells break away from the primary cancer, travel through the blood or lymph system, and form new, metastatic tumors in other parts of the body. The exact incidence of brain metastases is unknown, but it has been estimated that 98,000 to 170,000 new cases are diagnosed in the United States each year. Brain metastases occur in roughly 15% of all cancer patients, and we believe that approximately 40% of brain metastases are a result of NSCLC.

Learn more about METIS.

Read More

LUNAR

Cancer type: Non-small cell lung cancer (Phase 3 pivotal)

Protocol number: NCT02973789

About NSCLC: Lung cancer is the most common cause of cancer-related death worldwide, and non-small cell lung cancer accounts for approximately 85% of all lung cancers. Approximately 214,000 new cases of NSCLC are diagnosed in the U.S. each year.

Learn more about LUNAR.

Read More

INNOVATE

Cancer type: Ovarian carcinoma (Phase 2 pilot)

Protocol number: NCT02244502

About ovarian cancer: Ovarian cancer is the fifth most common cause of cancer death in women in the United States. The National Cancer Institute estimated that in 2016, there were approximately 22,000 new cases of ovarian cancer diagnosed and approximately 14,000 deaths in the United States. Ovarian cancer incidence increases with age, and the median age at time of diagnosis is 63 years old. The five-year survival rate is 44 percent, and the majority of patients present at advanced stage with 60 percent having metastatic disease.

Read More

PANOVA

Cancer type: Pancreatic adenocarcinoma (Phase 2 pilot)

Protocol number: NCT01971281

About pancreatic cancer: Most often diagnosed at a late stage, pancreatic cancer is one of the most lethal cancers. It is the fourth most frequent cause of death from cancer in the United States and is responsible for 7 percent of all U.S. cancer-related deaths. Unlike the decrease in mortality from other cancers over the past decade, pancreatic cancer death rates have been slowly increasing in the United States. Pancreatic cancer prognosis remains very poor, with a five-year survival of less than 8 percent. The National Cancer Institute estimated that, in 2016, there were approximately 53,000 new cases of pancreatic cancer diagnosed and approximately 41,000 deaths in the United States from pancreatic cancer.

Read More

STELLAR

Cancer type: Mesothelioma (Phase 2 pilot)

Protocol number: NCT02397928

About mesothelioma: Malignant mesothelioma is a rare thoracic solid tumor cancer that occurs in approximately 3,000 patients in the United States annually. Asbestos exposure has been strongly associated with the development of mesothelioma, which may occur many years later. Mesothelioma has a very poor prognosis, with a median overall survival of approximately 12 months in most reported studies.

Learn more about STELLAR.

Read More

additional research

Additional investigator-sponsored trials are also ongoing. For the most up-to-date clinical trial information, including protocol details, please visit the U.S. National Institutes of Health’s website at clinicaltrials.gov.

This information is for medical, and scientific and educational purposes only. TTFields are experimental for the treatment of patients with brain metastases, ovarian carcinoma, pancreatic adenocarcinoma, mesothelioma and non-small cell lung cancer. TTFields has not been approved by the U.S. Food and Drug Administration for commercial use in these indications. Limited by federal law to investigational use only.